Tengiz Tsertsvadze

Tengiz Tsertsvadze

Auto-generated profile, based on publicly available information

Tengiz Tsertsvadze

Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
AGAmiran Gamkrelidze
Amiran Gamkrelidze
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
AAAkaki Abutidze
Akaki Abutidze
LSLali Sharvadze
Lali Sharvadze
FAFrancisco Averhoff
Francisco Averhoff
Background: In April 2015, in collaboration with the US Centers for Disease Control and Prevention and Gilead Sciences, the country of Georgia embarked on the world’s first hepatitis C elimination program. We aimed to assess progress toward elimination targets 3 years after the start of the elimination program. Methods: We constructed a hepatitis C virus (HCV) care cascade for adults in Georgia, based on the estimated 150 000 persons aged ≥18 years with active HCV infection. All patients who were screened or entered the treatment program during April 2015–March 2018 were included in the analysis. Data on the number of persons screened for HCV were extracted from the national HCV screening database. For the treatment component, we utilized data from the Georgia National HCV treatment program database. Available treatment options included sofosbuvir and ledipasvir/sofosbuvir–based regimens. Results: Since April 2015, a cumulative 974 817 adults were screened for HCV antibodies; 86 624 persons tested positive, of whom 61 925 underwent HCV confirmatory testing. Among the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 45 334 (30.2%) initiated treatment with direct-acting antivirals, and 29 090 (19.4%) achieved a sustained virologic response (SVR). Overall, 37 256 persons were eligible for SVR assessment; of these, only 29 620 (79.5%) returned for evaluation. The SVR rate was 98.2% (29 090/29 620) in the per-protocol analysis and 78.1% (29 090/37 256) in the intent-to-treat analysis. Conclusions: Georgia has made substantial progress in the path toward eliminating hepatitis C. Scaling up of testing and diagnosis, along with effective linkage to treatment services, is needed to achieve the goal of elimination.

1 November 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
RKRussell R Kempker
Russell R Kempker
NDNatia Dvali
Natia Dvali
LALela Abashidze
Lela Abashidze
LSLali Sharavdze
Lali Sharavdze
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
Improved tests to diagnose latent TB infection (LTBI) are needed. We sought to evaluate the performance of two commercially available interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) for the diagnosis of LTBI and to identify risk factors for LTBI among HIV-infected individuals in Georgia, a country with high rates of TB.

3 February 2016 in Virology Journal
Verified
Journal Article
Open access
PDF file
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
LSLali Sharvadze
Lali Sharvadze
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
LDLela Dzigua
Lela Dzigua
MKMarine Karchava
Marine Karchava
KNKenrad E. Nelson
Kenrad E. Nelson
Hepatitis C virus (HCV) infection is a serious health problem in Georgia. We conducted a prospective study to identify and characterize the natural history of recent HCV infection since very first days of infection. Recent HCV infection was defined as detectable plasma HCV RNA in the absence of anti-HCV antibodies. A total of 7600 HCV seronegative blood donors and 3600 HCV seronegative drug users were screened for recent HCV infection. Among them 7 (0.09 %) blood donors and 10 (0.28 %) drug users tested positive for HCV RNA and were classified as having recent HCV infection. Of these 17 patients 4 (23.5 %) spontaneously cleared the virus by the end of 24 week follow-up. Five clinical forms of recent HCV infection were identified during the follow-up. Four patients had symptomatic disease, including 3 patients with jaundice and other clinical symptoms (2 of them cleared virus) and 1 patient only had other symptoms without jaundice. All symptomatic patients had ALT elevation. Three distinct variants of asymptomatic disease were identified in 13 patients: 9 patients had ALT elevation and none cleared the virus; 2 patients developed chronic disease without ALT elevation; 2 patients cleared virus without anti-HCV seroconversion and without ALT elevation; this form can be described as transitory HCV viremia. Additional studies are needed to define clinical and public health implications of transitory HCV viremia. Our study suggests the need for implementing nucleic acid testing of blood donors and key populations in order to more effectively identify HCV infected persons.

1 January 2014 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
LSLali Sharvadze
Lali Sharvadze
NDNatia Dvali
Natia Dvali
MKMarine Karchava
Marine Karchava
NRNino Rukhadze
Nino Rukhadze
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
Data on the effectiveness of second-line antiretroviral therapy (ART) in resource-limited countries of Eastern Europe is limited. Objective of this study was to evaluate virological outcomes of second-line ART in Georgia.

1 May 2018 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
NAN. Akhvlediani
N. Akhvlediani
IBI. Burjanadze
I. Burjanadze
DBD. Baliashvili
D. Baliashvili
TTT. Tushishvili
T. Tushishvili
MBM. Broladze
M. Broladze
GCG. Chanturia
G. Chanturia
Tularemia has sustained seroprevalence in Eurasia, with estimates as high as 15% in endemic regions. The purpose of this report is to characterise the current epidemiology of Francisella tularensis subspecies holarctica in Georgia. Three surveillance activities are summarised: (1) acute infections captured in Georgia's notifiable disease surveillance system, (2) infectious disease seroprevalence study of military volunteers, and (3) a study of seroprevalence and risk factors in endemic regions. Descriptive analyses of demographic, exposure and clinical factors were conducted for the surveillance studies; bivariate analyses were computed to identify risk factors of seropositivity using likelihood ratio χ2 tests or Fisher's exact tests. Of the 19 incident cases reported between 2014 and August 2017, 10 were confirmed and nine met the presumptive definition; the estimated annual incidence was 0.12/100 000. The first cases of tularemia in Western Georgia were reported. Seroprevalences of antibodies for F. tularensis were 2.0% for military volunteers and 5.0% for residents in endemic regions. Exposures correlated with seropositivity included work with hay and contact with multiple types of animals. Seroprevalence studies conducted periodically may enhance our understanding of tularemia in countries with dramatically underestimated incidence rates.

10 May 2019 in BMC Public Health
Verified
Journal Article
Open access
PDF file
AHAaron M. Harris
Aaron M. Harris
OCOtar Chokoshvili
Otar Chokoshvili
JBJoshua Biddle
Joshua Biddle
KTKostantine Turashvili
Kostantine Turashvili
MJMaia Japaridze
Maia Japaridze
FAFrancisco Averhoff
Francisco Averhoff
The country of Georgia has a high burden of chronic hepatitis C virus (HCV) infection, and prisoners are disproportionately affected. During 2013, a novel program offering no cost screening and treatment of HCV infection for eligible prisoners was launched. The HCV treatment program implemented a voluntary opt-in anti-HCV testing policy to all prisoners. Anti-HCV positive persons received HCV RNA and genotype testing. Transient elastography was also performed on prisoners with positive HCV RNA results. Prisoners with chronic HCV infection who had ≥F2 Metavir stage for liver fibrosis and a prison sentence ≥ 6 months were eligible for interferon-based treatment, which was the standard treatment prior to 2015. We conducted an evaluation of the HCV treatment program among prisoners from the program’s inception in December 2013 through April 2015 by combining data from personal interviews with corrections staff, prisoner data in the corrections database, and HCV-specific laboratory information. Of an estimated 30,000 prisoners who were incarcerated at some time during the evaluation period, an estimated 13,500 (45%) received anti-HCV screening, of whom 5175 (38%) tested positive. Of these, 3840 (74%) received HCV RNA testing, 2730 (71%) tested positive, and 880 (32%) met treatment eligibility. Of these, 585 (66%) enrolled; 405 (69%) completed treatment, and 202 (50%) achieved a sustained virologic response at least 12 weeks after treatment completion. HCV infection prevalence among Georgian prisoners was high. Despite challenges, we determined HCV treatment within Georgian Ministry of Correction facilities was feasible. Efforts to address HCV infection among prison population is one important component of HCV elimination in Georgia.